This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Fulgent Genetics (FLGT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Fulgent Genetics (FLGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Fulgent Genetics (FLGT)? Wall Street Analysts Think 27.22%
by Zacks Equity Research
The mean of analysts' price targets for Fulgent Genetics (FLGT) points to a 27.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Fulgent Genetics, Inc. (FLGT) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 148.39% and 3.37%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics (FLGT) Soars 6.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Fulgent Genetics (FLGT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 96.97% and 1.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
American Well Corporation (AMWL) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
American Well (AMWL) delivered earnings and revenue surprises of -38.89% and 2.58%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Privia Health (PRVA) Misses Q4 Earnings Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of -60% and 3.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 300% and 1.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of -21.88% and 31.46%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Olink Holding AB (publ) Sponsored ADR (OLK): Can Its 66.0% Jump Turn into More Strength?
by Zacks Equity Research
Olink Holding AB (publ) Sponsored ADR (OLK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 75.76% and 8.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Fulgent Genetics, Inc. (FLGT) and Masimo (MASI) have performed compared to their sector so far this year.
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 51.11% and 6.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Nyxoah SA (NYXH): Can Its 10.2% Jump Turn into More Strength?
by Zacks Equity Research
Nyxoah SA (NYXH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Are Medical Stocks Lagging Fulgent Genetics (FLGT) This Year?
by Zacks Equity Research
Here is how Fulgent Genetics, Inc. (FLGT) and Harrow Health (HROW) have performed compared to their sector so far this year.
Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Fulgent Genetics, Inc. (FLGT) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
Is Fulgent Genetics (FLGT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Fulgent Genetics, Inc. (FLGT) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
Fulgent Genetics, Inc. (FLGT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 14.29% and 13.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics, Inc. (FLGT) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 88.24% and 1.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics, Inc. (FLGT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 6.85% and 2.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics, Inc. (FLGT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Fulgent Genetics, Inc. (FLGT) closed at $58, marking a -1.46% move from the previous day.
Fulgent Genetics, Inc. (FLGT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Fulgent Genetics, Inc. (FLGT) closed at $58.31, marking a +0.4% move from the previous day.
Fulgent Genetics, Inc. (FLGT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) closed the most recent trading day at $54.65, moving -0.35% from the previous trading session.
Fulgent Genetics, Inc. (FLGT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) closed the most recent trading day at $49.73, moving -0.4% from the previous trading session.
Fulgent Genetics, Inc. (FLGT) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 14.12% and 6.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?